CLINICAL_TRIALS
trial_result
· 2025-02-28
Clinical Trial Update: Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia [Phase 2]
Summary
Phase 2 randomized trial comparing gilteritinib to midostaurin in FLT3-mutated acute myeloid leukemia; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: PrECOG, LLC. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-28